ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements with these filters
Sat Kartar Life allotted 26,95,200 convertible warrants at ₹172 each via preferential issue, raising ₹46.36 Crore. The company received 25% upfront subscription money from fourteen investors.
Sat Kartar Life Limited allotted 50,400 equity shares via preferential issue to Viney Growth Fund. The company raised ₹0.87 Crore to strengthen its overall capital base.
Sat Kartar Life Limited appointed M/s. R. S. Goel & Co and M/s. Rawal & Co. as Internal and Secretarial Auditors. The appointments cover financial year 2026-27.
Sat Kartar Life allotted 50,400 equity shares to Viney Growth Fund via a preferential issue. The company raised ₹0.87 Crore to strengthen its financial position.
Sat Kartar Life Limited allotted 26.95 lakh convertible warrants via preferential issue. The company raised ₹1.16 Crore as upfront subscription money to strengthen its capital base.
Sat Kartar Life approved allotting equity shares and convertible warrants totaling ₹47.22 Crore. The company also appointed new secretarial and internal auditors for FY 2026-27.
Sat Kartar Life Limited expanded its business activities into advertising, branding, and media planning. This strategic move aims to diversify revenue and leverage digital marketing expertise.
Sat Kartar Life Limited filed its annual Structured Digital Database compliance certificate for FY2026. The auditor confirmed total compliance with insider trading regulations.
Sat Kartar Life Limited clarified missing IPO proceeds utilization details for its March 2026 results. The company raised ₹33.80 Crore, correcting a prior regulatory reporting omission.
Sat Kartar Life Limited conducted an EGM on May 13, 2026. Shareholders approved the preferential issuance of equity shares and warrants to non-promoter entities.
Sat Kartar Life reported 23% revenue growth crossing ₹200cr in FY26. Transitioning from product-focused to an integrated Ayurvedic healthcare ecosystem including hospitals.
Sat Kartar Life Limited received NSE in-principle approval for issuing 2,824,800 equity shares. The allotment follows warrant conversions from a prior preferential issue.
Sat Kartar Life Limited is adopting a new spiritual and wellness business line. The expansion leverages its existing digital reach to drive revenue and operational synergies.
Sat Kartar Life transitioned from a product-focused entity to a healthcare ecosystem, delivering record growth in FY26. Management is aggressively targeting 150% revenue growth by FY28 through massive hospital bed expansion and US market entry.
Sat Kartar Life Limited received a no-objection letter from the NSE to reclassify SK Sarthi Private Limited from 'Promoter Group' to 'Public' shareholder category. The entity holds less than 1% of the company's paid-up capital, making shareholder approval unnecessary. This regulatory milestone follows the company's initial application submitted in January 2026.
Sat Kartar Life Limited reported strong FY26 results with consolidated revenue of ₹200.70 Crore, up 23.19% YoY. Net profit (PAT) rose 74.31% to ₹17.10 Crore. The company launched its first 30-bed Ayurveda hospital in Delhi and raised ₹48.58 Crore to support its expansion towards a ₹500 Crore revenue target by FY28.
Sat Kartar Life Limited submitted its Monitoring Agency Report for the half-year ended March 31, 2026. The report, issued by CARE Ratings, monitors the utilization of ₹33.80 Crore raised through its IPO. No deviations from the stated objects were reported during the period.
Sat Kartar Life Ltd reported revenue from operations of ₹110.6 Cr (+27.0% YoY) and net profit of ₹9.8 Cr (+63.3% YoY) for H2 FY26.
Sat Kartar Life Limited reported consolidated annual revenue of ₹203.12 Crore and net profit of ₹17.10 Crore for FY2026. Standalone revenue reached ₹193.84 Crore. The auditors issued an unmodified opinion, reflecting stable financial reporting and significant year-on-year growth in both top and bottom lines.
Sat Kartar Life Limited issued a corrigendum for a proposed preferential issue of 27,74,400 convertible warrants at ₹172 each, totaling ₹47.72 Crore. The funds will be utilized for healthcare expansion, strategic acquisitions, and technology branding. The warrants are convertible into equity shares within 18 months.
Sat Kartar Life Limited has scheduled a board meeting for May 5, 2026, to consider and approve audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window remains closed until 48 hours after the results announcement.
Sat Kartar Life Limited (formerly Sat Kartar Shopping Limited) confirmed it does not qualify as a Large Corporate for FY 2025-26. The company reported outstanding borrowings of ₹2.39 Crore as of March 31, 2026. This mandatory SEBI disclosure clarifies the company's debt-raising compliance framework.
Sat Kartar Shopping Limited has convened an Extra-ordinary General Meeting (EGM) on May 13, 2026. Shareholders will vote on special resolutions regarding the preferential issuance of equity shares and warrants to non-promoter categories. The meeting will be conducted via video conferencing.
Sat Kartar Life Limited convened an EGM for May 13, 2026, to approve raising ₹48.59 Crore via preferential issuance of 50,400 equity shares and 27,74,400 warrants to non-promoter investors. Proceeds will fund healthcare expansion, strategic acquisitions, and technology branding over 24 months.
Sat Kartar Shopping Limited is acquiring the remaining stake in Plantomed Neutraceuticals Private Limited for ₹1.21 Crore to make it a wholly-owned subsidiary. The acquisition of the Ayurveda healthcare company aims to consolidate brands and expand the product portfolio. The transaction is expected to be completed by May 15, 2026.
Sat Kartar Shopping Limited approved the acquisition of a further 24% stake in Plantomed Neutraceuticals Private Limited for ₹1.21 Crore. This transaction will increase the company's control to 100%, making the target a wholly-owned subsidiary. The acquisition aims to consolidate branding and expand the company's Ayurveda and wellness product portfolio by May 2026.
Sat Kartar Life Limited approved the acquisition of an additional 24% stake in Plantomed Nutraceuticals Private Limited for ₹1.21 Crore. The transaction will make the target a wholly-owned subsidiary, aiding brand consolidation and aligning operations with the company's long-term vision. The deal is expected to close by May 15, 2026.
Sat Kartar Life Limited's board approved raising ₹49.79 Crore through the preferential issuance of equity shares and convertible warrants to non-promoter investors. Additionally, the company will acquire the remaining 24% stake in Plantomed Neutraceuticals for ₹1.21 Crore to make it a wholly-owned subsidiary. An EGM is scheduled for May 13, 2026, to seek shareholder approval.
Sat Kartar Shopping Limited has received formal approval from the National Stock Exchange of India to change its name to Sat Kartar Life Limited. The name change is effective in exchange records from April 23, 2026.
Sat Kartar Shopping Limited will change its name to Sat Kartar Life Limited, effective April 23, 2026. The company's trading symbol remains SATKARTAR on the NSE. This administrative update reflects a corporate rebranding.